Compare Novavax Inc (NVAX) vs AT&T Inc. (T) Price & Performance

Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.

The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.

AT&T (T) trades at $24.08, up 1.18% with a bullish technical signal and strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.65 exceeding expectations. Valuation remains attractive with a P/E of 8.1 and dividend yield of 4.7%. Recent developments include fiber expansion and AI initiatives, while cash flow improved to $15.1B in 2025. Technical indicators show bullish moving averages with resistance near $24-25.

Outlook remains positive with 15% upside to consensus price target of $27.69. Investment appeal includes strong cash flow generation, dividend sustainability, and ongoing network investments. Key risks include competitive pressure from SpaceX's wireless ambitions and execution challenges in fiber deployment. Analyst consensus leans bullish with 41% buy ratings versus 10% sell recommendations.